{
    "nct_id": "NCT01142258",
    "title": "Trazodone for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomised, Double-blind, Placebo-controlled Study",
    "status": "COMPLETED",
    "last_update_time": "2012-10-12",
    "description_brief": "The purpose of this study is to determine whether trazodone is effective in the treatment of sleep disorders in Alzheimer's disease (AD).",
    "description_detailed": "Sleep disorders (SD) affects 35 to 50 percent of patients with AD. These disorders often make caring for patients at home very difficult. Trazodone is commonly prescribed drugs for SD in AD patients. There are no controlled studies in this sample of patients for this purpose.",
    "phase": [
        "PHASE3"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "neuropsychiatric symptom improvement",
    "drug": [
        "trazodone"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The intervention is trazodone, an antidepressant (serotonin antagonist and reuptake inhibitor, SARI) with sedative properties that is commonly used off-label to treat insomnia and sleep disturbance in older adults and people with dementia. The trial title and purpose state the drug is being tested for treatment of sleep disorders in Alzheimer\u2019s disease, which is symptomatic (sleep/behavioral) management rather than targeting AD pathology (amyloid/tau). \ue200cite\ue202turn0search1\ue202turn0search0\ue201",
        "Act (web search results and extraction):\n- StatPearls (NCBI Bookshelf): summarizes trazodone as a SARI antidepressant, notes off-label use for insomnia and use in Alzheimer disease/dementia for behavioral symptoms, and that trazodone is not FDA-approved for sleep disorders. \ue200cite\ue202turn0search1\ue201\n- PubMed review/meta-commentary: discusses trazodone\u2019s pharmacology (5-HT2A and \u03b11 antagonism, weak SERT inhibition), its sleep effects (improves slow-wave sleep), and observational data suggesting trazodone use for sleep was associated with slower cognitive decline in one cohort \u2014 highlighting symptomatic sleep benefits rather than direct disease-modifying action. \ue200cite\ue202turn0search0\ue202turn0search2\ue201\n- Systematic review / meta-analysis (PMC): shows trazodone affects polysomnographic sleep architecture and is used as a hypnotic in studies, but practice guidelines caution limited evidence for routine use. \ue200cite\ue202turn0search4\ue201\nExtracted trial detail: randomized, double-blind, placebo-controlled test of trazodone vs placebo for sleep disorders in AD \u2014 objective is to improve a neuropsychiatric/sleep symptom. (User-provided trial title and purpose.)",
        "Reflect: Classification check \u2014 trazodone is a small-molecule antidepressant but in this trial it is being used to treat sleep disturbance (a neuropsychiatric/symptom outcome) rather than to modify Alzheimer\u2019s pathology or primarily to enhance cognition. Therefore the correct category among the four provided is 'neuropsychiatric symptom improvement'. No strong ambiguity: although trazodone is a small molecule, the category definitions distinguish disease-targeted small molecules (pathology-directed) from symptomatic agents; trazodone here is symptomatic. Citations above support trazodone\u2019s pharmacology and its off-label use for sleep in AD. \ue200cite\ue202turn0search1\ue202turn0search2\ue202turn0search4\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests trazodone, a small\u2011molecule antidepressant/sedative whose primary pharmacology is modulation of monoaminergic neurotransmission (potent 5\u2011HT2A and \u03b11\u2011adrenergic antagonism, weak serotonin reuptake inhibition, plus antihistaminic effects). In this study it is being used to treat sleep disturbance (a neuropsychiatric/symptomatic outcome) rather than to target AD pathology (amyloid or tau). This pharmacology maps to CADRO category D: Neurotransmitter Receptors.",
        "Act: Extracted details \u2014 trazodone; mechanism: serotonin 5\u2011HT2A antagonism, weak SERT inhibition, \u03b11\u2011adrenergic and H1 histamine effects; indication in this trial: symptomatic treatment of sleep disorders in Alzheimer\u2019s disease. Sources supporting these points: REST trial / JAD methods describing trazodone for sleep in prodromal AD/aMCI. \ue200cite\ue202turn0search0\ue201; JAD commentary and cohort data describing trazodone\u2019s receptor profile and SWS effects. \ue200cite\ue202turn0search1\ue202turn0search4\ue201; systematic review/meta\u2011analysis showing trazodone\u2019s effects on polysomnography (increased total sleep time and N3/SWS). \ue200cite\ue202turn0search3\ue201. (A large naturalistic cohort with null findings for cognition is noted for balance.) \ue200cite\ue202turn0search2\ue201.",
        "Reflect: Classification check \u2014 trazodone is not being trialed here to modify amyloid, tau, inflammation, proteostasis, vasculature, or other AD core pathologies, but to modify neurotransmitter systems to improve sleep (a neuropsychiatric symptom). Therefore CADRO D) Neurotransmitter Receptors is the most specific and appropriate category. If the trial instead aimed to alter AD biology (e.g., slow amyloid accumulation via sleep), one could consider additional categories, but the stated aim and mechanism are symptomatic neurotransmitter modulation."
    ]
}